D-Fi not checked

Castle Creek Biosciences, LLC.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“D-Fi is composed of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.”In the company’s words, NCT06892639 on ClinicalTrials.gov
Tested for
Dystrophic Epidermolysis Bullosa
Main trialPhase 3
“The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.”In the company’s words, NCT06892639 on ClinicalTrials.gov

Other drugs for Dystrophic Epidermolysis Bullosa

All 8 drugs for Dystrophic Epidermolysis Bullosa

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting Sep 2027 Evaluation of D-Fi for the Treatment of Wounds Due to DEB
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow D-Fi

Following is part of Solo: you see every change to D-Fi the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in